NeoGenomics to Report First Quarter 2025 Financial Results on April 29, 2025
NeoGenomics (NASDAQ: NEO), a leading oncology diagnostic solutions provider, has scheduled its first quarter 2025 financial results announcement for Tuesday, April 29, 2025, before U.S. markets open. The company will host a webcast and conference call at 8:30 a.m. ET to discuss the results and recent highlights.
Investors can access the live webcast through the company's Investor Relations website at ir.neogenomics.com. For telephone access, participants should dial (888) 506-0062 (domestic) or (973) 528-0011 (international) using access code 603651.
NeoGenomics (NASDAQ: NEO), un fornitore leader di soluzioni diagnostiche oncologiche, ha programmato l'annuncio dei risultati finanziari del primo trimestre 2025 per martedì 29 aprile 2025, prima dell'apertura dei mercati statunitensi. L'azienda ospiterà un webcast e una conferenza telefonica alle 8:30 a.m. ET per discutere i risultati e i recenti sviluppi.
Gli investitori possono accedere al webcast dal vivo tramite il sito web delle Relazioni con gli Investitori dell'azienda all'indirizzo ir.neogenomics.com. Per l'accesso telefonico, i partecipanti devono comporre il numero (888) 506-0062 (nazionale) o (973) 528-0011 (internazionale) utilizzando il codice di accesso 603651.
NeoGenomics (NASDAQ: NEO), un proveedor líder de soluciones de diagnóstico oncológico, ha programado el anuncio de sus resultados financieros del primer trimestre de 2025 para el martes 29 de abril de 2025, antes de la apertura de los mercados en EE. UU. La empresa llevará a cabo un webcast y una conferencia telefónica a las 8:30 a.m. ET para discutir los resultados y los aspectos destacados recientes.
Los inversores pueden acceder al webcast en vivo a través del sitio web de Relaciones con Inversores de la empresa en ir.neogenomics.com. Para el acceso telefónico, los participantes deben marcar el (888) 506-0062 (nacional) o el (973) 528-0011 (internacional) utilizando el código de acceso 603651.
NeoGenomics (NASDAQ: NEO), 선도적인 종양학 진단 솔루션 제공업체가 2025년 4월 29일 화요일에 미국 시장 개장 전에 2025년 1분기 재무 결과 발표를 예정하고 있습니다. 회사는 동부 표준시 기준 오전 8시 30분에 결과 및 최근 하이라이트에 대해 논의하기 위해 웹캐스트 및 전화 회의를 개최합니다.
투자자는 회사의 투자자 관계 웹사이트인 ir.neogenomics.com을 통해 실시간 웹캐스트에 접속할 수 있습니다. 전화로 접속하려면 참가자는 (888) 506-0062 (국내) 또는 (973) 528-0011 (국제)로 전화하여 액세스 코드 603651을 사용해야 합니다.
NeoGenomics (NASDAQ: NEO), un fournisseur leader de solutions de diagnostic en oncologie, a prévu l'annonce de ses résultats financiers du premier trimestre 2025 pour mardi 29 avril 2025, avant l'ouverture des marchés américains. L'entreprise organisera un webinaire et une conférence téléphonique à 8h30 ET pour discuter des résultats et des points saillants récents.
Les investisseurs peuvent accéder au webinaire en direct via le site web des Relations Investisseurs de l'entreprise à l'adresse ir.neogenomics.com. Pour un accès téléphonique, les participants doivent composer le (888) 506-0062 (national) ou le (973) 528-0011 (international) en utilisant le code d'accès 603651.
NeoGenomics (NASDAQ: NEO), ein führender Anbieter von Onkologie-Diagnoselösungen, hat die Bekanntgabe seiner finanziellen Ergebnisse für das erste Quartal 2025 auf Dienstag, den 29. April 2025, vor der Eröffnung der US-Märkte angesetzt. Das Unternehmen wird um 8:30 Uhr ET ein Webcast und eine Telefonkonferenz abhalten, um die Ergebnisse und die jüngsten Höhepunkte zu besprechen.
Investoren können über die Investor-Relations-Website des Unternehmens unter ir.neogenomics.com auf den Live-Webcast zugreifen. Für den telefonischen Zugang sollten die Teilnehmer (888) 506-0062 (national) oder (973) 528-0011 (international) mit dem Zugangscode 603651 wählen.
- None.
- None.
The live webcast may be accessed by visiting the Investor Relations section of our website at ir.neogenomics.com or by clicking here. The webcast will be archived and available for replay shortly after the conclusion of the call.
To access the live call via telephone, dial (888) 506-0062 (domestic) or (973) 528-0011 (international) at least five minutes prior to the call. The participant access code is 603651.
About NeoGenomics, Inc.
NeoGenomics, Inc. is a premier cancer diagnostics company specializing in cancer genetics testing and information services. We offer one of the most comprehensive oncology-focused testing menus across the cancer continuum, serving oncologists, pathologists, hospital systems, academic centers, and pharmaceutical firms with innovative diagnostic and predictive testing to help them diagnose and treat cancer. Headquartered in
View source version on businesswire.com: https://www.businesswire.com/news/home/20250408638953/en/
Investor Contact
Kendra Sweeney
kendra.sweeney@neogenomics.com
Media Contact
Andrea Sampson
asampson@sampsonprgroup.com
Source: NeoGenomics, Inc.
FAQ
When will NeoGenomics (NEO) release Q1 2025 earnings?
How can investors join NeoGenomics (NEO) Q1 2025 earnings call?
What time is NeoGenomics (NEO) Q1 2025 earnings call?
Will NeoGenomics (NEO) Q1 2025 earnings call be archived?
